Results 251 to 260 of about 137,826 (378)
Abstract Exposure levels without appreciable human health risk may be determined by dividing a point of departure on a dose–response curve (e.g., benchmark dose) by a composite adjustment factor (AF). An “effect severity” AF (ESAF) is employed in some regulatory contexts.
Barbara L. Parsons +17 more
wiley +1 more source
Regulators of homologous recombination deficiency identified by machine learning using somatic multi-omics data. [PDF]
Valieris R +8 more
europepmc +1 more source
Advances in Double‐Stranded DNA Targeting Technologies
Double‐stranded DNA (dsDNA) plays a crucial role in genetic information storage and disease management, but its inherent stability limits access to internal bases. To overcome this challenge, various high‐specificity molecular targeting technologies have been developed to destabilize the DNA structure.
Zuhao Shen +8 more
wiley +1 more source
Interaction between ENPP1 and homologous recombination deficiency defines distinct pan-cancer signatures: A retrospective observational study. [PDF]
Kim YM +6 more
europepmc +1 more source
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer.
P. Konstantinopoulos +3 more
semanticscholar +1 more source
Comprehensive genomic profiling for homologous recombination deficiency guides PARP inhibitor therapy recommendations in ovarian cancer. [PDF]
Inci A +5 more
europepmc +1 more source
The prognostic and predictive value of homologous recombination deficiency in gastrointestinal cancer. [PDF]
Jiang B +10 more
europepmc +1 more source
Abstract Genetic tumor risk syndromes (genturis) contribute substantially to the overall cancer burden and provide opportunities for early detection, prevention, and individualized treatment. Yet, many affected individuals remain undiagnosed due to restrictive testing criteria and challenges in variant interpretation.
Mayra Sauer +11 more
wiley +1 more source

